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Targeted delivery of a photosensitizer to Aggregatibacter
actinomycetemcomitans biofilm
Abstract
The ability to selectively target specific biofilm species with antimicrobials would enable control over
biofilm consortium composition, with medical applications in treatment of infections on mucosal
surfaces that are colonized by a mixture of beneficial and pathogenic microorganisms. We
functionalized a genetically engineered multimeric protein with both a targeting moiety (biotin) and
either a fluorophore or a photosensitizer (SnCe6). Biofilm microcolonies of Aggregatibacter
actinomycetemcomitans, a periodontal pathogen, were targeted with the multifunctional dodecamer.
Streptavidin was used to couple biotinylated dodecamer to a biotinylated anti-A.
actinomycetemcomitans antibody. This modular targeting approach enabled us to increase the loading of
photosensitizer onto the cells by a cycle of amplification. Scanning laser confocal microscopy was used
to characterize transport of fluorescently tagged dodecamer into the microcolonies and targeting of the
cells with biotin-labeled, fluorescently tagged dodecamer. Light-induced activity of the targeted
photosensitizer reduced the viability of A. actinomycetemcomitans biofilm, as indicated by membrane
permeability to propidium iodide. The functionalized multimeric protein promises to be a useful tool for
controlling periodontal biofilm consortia and offers a modular design whereby moieties that target
different species can be readily combined with the functionalized protein construct.
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 2 
Abstract 1 
 2 
 The ability to selectively target specific biofilm species with antimicrobials would enable 3 
control over biofilm consortia composition, with medical applications in treatment of infections on 4 
mucosal surfaces that are colonized by a mixture of beneficial and pathogenic microorganisms. We 5 
functionalized a genetically engineered multimeric protein with both a targeting moiety (biotin) and 6 
either a fluorophor or a photosensitizer (SnCe6). Biofilm microcolonies of Aggregatibacter 7 
actinomycetemcomitans (Aa), a periodontal pathogen, were targeted with the multifunctional 8 
dodecamer. Streptavidin was used to couple biotinylated dodecamer to a biotinylated anti-Aa 9 
antibody. This modular targeting approach enabled us to increase the loading of photosensitizer onto 10 
the cells by a cycle of amplification. Scanning laser confocal microscopy (SLCM) was used to 11 
characterize transport of fluorescently tagged dodecamer into the microcolonies and targeting of the 12 
cells with biotin labeled, fluorescently tagged dodecamer. Light induced activity of the targeted 13 
photosensitizer reduced the viability of A. actinomycetemcomitans biofilm, as indicated by 14 
membrane permeability to propidium iodide. The functionalized multimeric protein promises to be a 15 
useful tool for controlling periodontal biofilm consortia and offers a modular design whereby 16 
moieties that target different species can be readily combined with the functionalized protein 17 
construct.     18 
     19 
Introduction 20 
 Therapeutic tools that enabled targeted delivery of antimicrobials to specific species in 21 
biofilms would expand our capability to treat chronic infections associated with mucosal surfaces 22 
where complete sterility is not the natural healthy condition. The oral cavity and the gut are prime 23 
examples of mucosal surfaces at which the immune system maintains a healthy microbial presence 24 
(3, 50). Mucosal surfaces in the oral cavity are non-sterile environments colonized by biofilm 25 
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 3 
consortia (38). In the gut, some commensals are true symbionts (30, 36) and, similarly, it is 1 
hypothesized that oral commensals may aid in maintaining a healthy immune homeostasis (35). The 2 
implication is that treatment of oral diseases such as periodontal disease can be made more effective 3 
by selective elimination of pathogens. By extension, we may also find that tools that enable specific 4 
targeting of biofilm pathogens provide effective treatments for chronic infections of the gut (31). 5 
  A class of multimeric proteins that self assemble into highly symmetric quaternary structures 6 
(7, 52) show promise for development into delivery vehicles for therapeutic (15, 16, 44) and 7 
imaging agents (41, 51). We selected one of these proteins, a relatively small spherical 9 nm 8 
diameter dodecamer, originally isolated from Listeria innocula (LiDps) (23), for targeted delivery of 9 
a photosensitizer to A. actinomycetemcomitans biofilm. We genetically added a tetrapeptide to the C 10 
terminus of each of the 12 monomeric 18k Da subunits of LiDps. Cysteines incorporated into this 11 
tetrapeptide were labeled with biotin. Since the C terminus is presented on the exterior surface of the 12 
assembled dodecamer these biotins were readily available for binding to streptavidin, a universal 13 
coupling protein. A SnCe6 photosensitizer was covalently linked to intrinsic lysines. 14 
 Photosensitizers are compounds that produce reactive oxygen species (ROS) upon excitation 15 
by light (25). Antimicrobial photodynamic therapy (PDT) has been shown to be effective against 16 
oral pathogens (6, 29, 54). SnCe6 has been used previously for targeted antimicrobial PDT (10-12). 17 
The primary modes of action of photosensitizers are membrane disruption and, if the photosensitizer 18 
is internalized, DNA damage (19). The antimicrobial activity of ROS produced by light activated 19 
photosensitizers is relatively localized. This is especially the case for singlet oxygen (diffusion 20 
length of < 50 nm), which is thought to be the primary ROS causing cell death (32). The localized 21 
action of photosensitizers makes them attractive agents for targeted antimicrobial therapy. 22 
 The LiDps genetic construct, dual functionalized with SnCe6 and biotin, is a modular unit 23 
that can be combined with any targeting moiety that can be biotinylated. This would accommodate a 24 
variety of approaches that have been used to target microbial pathogens including 25 
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 4 
lectin/carbohydrate interactions (53), antimicrobial peptides (8, 21), and the lysins isolated from 1 
bacteriophage (14). We chose to use an antibody as the targeting moiety for these studies since 2 
monoclonal antibodies are available for a number of the prevalent periodontal pathogens (5, 9, 17). 3 
In addition, antibodies offer a wide range of potential cell surface targets combined with the 4 
possibility to engineer high binding affinities (4). 5 
 A. actinomycetemcomitans is a gram negative periodontal pathogen implicated as the 6 
primary etiological agent in localized aggressive periodontitis (13, 37). Rough colony variants 7 
isolated from sites of infection form discrete microcolonies when cultured in vitro which exhibit 8 
distinctive cohesive as well as adhesive properties (27). We characterized transport of the LiDps 9 
dodecamer to the base of A. actinomycetemcomitans  microcolonies, demonstrated targeting of the 10 
LiDps to the cells in the microcolonies and showed that SnCe6 targeted to 24 h biofilms produced 11 
light activated membrane disruption. The modular design enabled us to use cycles of alternating 12 
exposure to the streptavidin and the LiDps dodecamer to increase the loading of targeted 13 
photosensitizer onto the cells.    14 
 15 
Methods 16 
Bacterial strain and culture conditions 17 
 A. actinomycetemcomitans (formerly Actinobacillus actinomycetemcomitans) strain D7, a 18 
rough colony clinical isolate obtained from the central incisor of an African American female patient 19 
with generalized aggressive periodontitis, was provided by Casey Chen, University of Southern 20 
California. The liquid medium was modified tryptic soy broth (MTSB) consisting of (per liter): 30 g 21 
tryptic soy broth and 3 g yeast extract. Solid medium was MTSB with 50 ml fetal bovine serum 22 
(HyClone) and 15 g bacto agar added (per liter). Frozen stocks were maintained at -80oC in 20% 23 
glycerol, 80% MTSB. Biofilms were cultured in 96 well microtiter plates with glass bottoms 24 
(MatTek Corp., P96G-1.5-5-F) to enable confocal laser scanning microscope (CLSM) images to be 25 
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 5 
acquired. The biofilm inoculum was prepared by looping single colonies, cultured on solid medium 1 
at 37 oC in 5% CO2 for 72h, into a 1 ml aliquot of liquid medium and dispersing the suspension of 2 
cell aggregates by repeated pipetting followed by vortexing and finally diluting the suspension to 3 
obtain approximately 107 CFU/ml. No attempt was made to isolate single cells from cell aggregates 4 
as described by Kaplan (27). Biofilms were cultured at 37oC in 5% CO2. Medium was replaced at 24 5 
h for biofilms cultured for 48h.   6 
Antibody  7 
 Monoclonal antibody (Aa-mAb) 225AA2 (18) against A. actinomycetemcomitans, isotype 8 
mIgG2b, was purified by affinity chromatography on an AffinityPakTM Protein A column (Thermo 9 
Fisher Scientific) following the manufacturer’s recommendations with slight modifications: the 10 
wash buffer was Dulbecco’s PBS, pH 8.2 and the elution buffers were 0.1M sodium citrate at pH 11 
5.0, 4.0 and 3.0. Fractions eluted from the column were concentrated to an OD280 of approximately 12 
0.2 and dialyzed into 50 mM HEPES (150 mM NaCl, pH 7.0). Purity of Aa-mAb was confirmed by 13 
SDS-PAGE under reducing conditions to separate the light and heavy chains. Aa-mAb was 14 
biotinylated by reaction for 1 h at room temperature with 0.5 mM of a succinimidyl ester of biotin 15 
incorporating a hydrophilic spacer (NHS-PEG4-Biotin, EZ-Link, Thermo Scientific Pierce, 21362). 16 
Unreacted reagent was separated from the Aa-mAb using a BioRad spin column (equilibrated in 17 
10mM Tris, pH 7.4). Immuno dot blots were used to confirm the association of the biotin with Aa-18 
mAb and to check the integrity of the epitope binding site. The covalent addition of the biotin 19 
reagent to the light chain of the Aa-mAb was further confirmed by liquid 20 
chromatography/electrospray mass spectrometry (LC/MS) as described previously (41). Only the 21 
light chain (biotinylated or non-biotinylated) could be detected with LC/MS. 22 
 The Aa-mAb 225AA2 epitope has not been characterized at the molecular level. However, 23 
its specificity has been characterized (18). The Aa-mAb 225AA2 bound to every A. 24 
actinomycetemcomitans strain tested (18 strains with 5 different serotypes) and was negative for all 25 
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 6 
non- A. actinomycetemcomitans strains tested consisting of 55 species known to be prominent in the 1 
oral cavity (17 genera). 2 
LiDps mutagenesis and expression 3 
 Addition of residues KLFC to the C-termini of wt LiDps subunit was accomplished by a 4 
modification of the QuikChange site-directed mutagenesis (Stratagene) using primers containing 5 
extra nucleotides and pET-30b based plasmids containing the wild type LiDps sequence as a 6 
template. Primers for mutagenesis contained the nucleotide for the KLFC tetrapeptide (Forward 7 
primer: 5’ AAGGATCCGAATTCGAGCTCCGTCGAC  3’; Reverse primer: 5’ 8 
AAGGATCCTTAGCAGAATAGCTTTTCTAA GGAGCTTTTCC  3’). The amplified DNAs were 9 
transformed into competent E.coli strain BL21 (DE) (Novagen). For expression and purification of 10 
the assembled KLFC LiDps cultures of the transformed cells were grown overnight at 37 °C in 11 
LB/Kanomycin 30 mg/ml. Protein expression was induced with 1.0mM isopropyl-D-12 
thiogalactopyranoside for 5 h. Cells were pelleted at 3700 x g and resuspended in 50mM MES 13 
(pH6.5, 100 mM NaCl) with lysozyme (50 µm/ml), RNase (90 µm/ml), and DNase (60 µm/ml). A 14 
sequence of sonication and French press treatment were used to lyse cells. Cell fragments were 15 
removed by centrifugation at 12000 x g and the supernatant heated to 65 oC for 10 min. The 16 
suspension was centrifuged at 12000 x g to remove the aggregated heat sensitive proteins. 17 
Assembled KLFC LiDps was further purified by size exclusion chromatography (SEC) (Superose 6, 18 
Amersham Biosciences, Uppsala, Sweden). Identity and purity of the KLFC LiDps protein was 19 
confirmed by LC/MS, SDS-PAGE and TEM.    20 
Functionalization of the KLFC-LiDps 21 
 Purified KLFC-LiDps was biotinylated by reaction of  2 mg/ml protein (0.1 mM protein 22 
subunit) with 2 mM of maleimide PEG2 biotin (EZ-link, Pierce, 21901) for 3h at room temperature 23 
in MES buffer (pH 6.5, 100 mM NaCl). KLFC LiDps incorporates no cysteine residues except for 24 
those added genetically and maleimides react specifically with cysteines of proteins (22).  25 
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 7 
Assembled dodecamer was purified from the reaction mixture by SEC. Covalent addition of biotin 1 
to the protein subunits was confirmed using LC/MS. For transport studies fluorescein was added to 2 
the cysteines of the KLFC tetrapeptide using the same protocol but with fluorescein-5 maleimide 3 
reagent (Invitrogen). A fluorescent tag (Alexa Fluor 488, Invitrogen) or the photosensitizer (Sn(IV) 4 
Chlorin e6, Frontier Scientific, Logan UT) were added to lysines of biotinylated LiDps by reaction 5 
with succinimidyl esters. The succinimidyl ester of Alexa Fluor 488 was purchased (Invitrogen, 6 
A20000). Carboxylate groups of the succinimidyl ester of the SnCe6 were converted to succinimidyl 7 
esters using a modification of a previously published protocol (10). Sn(IV) Chlorin e6 (7 mg),  1-(3-8 
(dimethylamino)propyl)-3-ethylcarbodiimide hydroxychloride (3 mg) and N-hydroxysuccinimide (4 9 
mg) were combined in a flame dried glass anaerobe jar which was placed in an anaerobe chamber. 10 
To this was added 1 ml of dimethylformamide (dry, stored under nitrogen), the jar was sealed and 11 
the mixture was allowed to react for approximately 12 h with mixing. The reaction mixture was 12 
aliquoted into 50 µl portions, flash frozen in liquid nitrogen and lyophilized. The succinimidyl esters 13 
of the Alexa Fluor 488 or SnCe6 were added to the biotinylated KLFC-LiDps by reaction of  1 14 
mg/ml protein (0.05 mM protein subunit) with 0.5 mM of the reagent for 3h at room temperature in 15 
50 mM phosphate buffer (pH 7.5, 100 mM NaCl).  The latter reaction was performed anaerobically 16 
in the dark. Prior to addition of the SnCe6 succinimidyl ester nitrogen gas was bubbled through the 17 
protein solution for 10 min. The solution was then transferred immediately into an anaerobe 18 
chamber, the reagent was added and the mixture was covered with foil and mixed. KLFC-LiDps 19 
fluorescently tagged or labeled with SnCe6 was purified by SEC as described above. According to 20 
spectrophotometric determination the ratio of labeling of the Alexa Fluor 488 and SnCe6 were both 21 
approximately 4 per dodecamer of LiDps . Extensive dialysis did not decrease these ratios. We 22 
further measured the extent of non-specific binding of SnCe6 to the dodecamer. Dodecamer was 23 
exposed to SnCe6 under identical conditions to those used for reaction with the succinimidyl ester of 24 
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 8 
SnCe6. In this case co-migration of the absorbance originating from SnCe6 with the dodecamer was 1 
negligible.  2 
Transport and targeting of the KLFC-LiDps  3 
 Transport of dodecamer into A. actinomycetemcomitans biofilm microcolonies and targeting 4 
of dodecamer to the microcolonies was characterized using SLCM (Leica TCS-SP2-AOBS). 5 
Biofilm microcolonies were visualized through the glass coverslip floor of the wells. This was 6 
accomplished by filling each well to the brim, covering the row of wells with parafilm and inverting 7 
the plate. Images were collected with either 40X 0.8 NA or 63X 0.9 NA HCX APO L U-V-I water 8 
immersion objectives. Green and red fluorophors were discriminated by Acousto-optical tunable 9 
filters. Green fluorophors (Fluorescein, SYTO 9 (Invitrogen) and Alexa Fluor 488) were excited 10 
with a 488 nm laser, and fluorescence was collected from 500 nm to 543 nm.  Red fluorophors 11 
(SYTO 59 (Invitrogen) and propidium iodide (Sigma-Aldrich)) were excited with a 561 nm laser, 12 
and fluorescence was collected from 600 nm to 721 nm.  Images were taken at 1.0 µm intervals 13 
throughout the depth of the biofilms. Stacks were combined in Imaris software (Bitplane AG, 14 
Zürich, Switzerland) to yield final images. Transport was evaluated by exposing the biofilm to 1 15 
mg/ml KLFC-LiDps labeled with fluorescein and then tracking changes in the fluorescence at the 16 
base of the biofilm. Biofilm microcolonies were pre-stained with SYTO 59 for this study so that 17 
biofilm microcolonies could be located and brought into approximate focus which required about 3 18 
min after filling the well with the protein solution. Images of the biofilm were acquired at 19 
approximately 4 min intervals by repeating the scan using the same parameters. The fluorescence 20 
increase in areas at the base of microcolonies was assessed as mean pixel brightness using Adobe 21 
Photoshop (7.0). The colonies stained heavily with the SYTO 59 nucleic acid stain resulting in 22 
strong red fluorescence and slight bleed through into the green channel. The corresponding pixel 23 
brightness of this bleed through was treated as background which was subtracted from the raw data 24 
values. Targeting was performed by exposing biofilms to a series of solutions in the wells. Biofilms 25 
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 9 
were first washed with 1% BSA in 10 mM PBS (pH 7.0, 100 mM NaCl) for 5 min. Biofilms were 1 
rinsed with PBS after each reaction. Solutions and exposure times were: Biotinylated Aa-mAb at 2 
approximately 50 µg/ml for 50 min, streptavidin at 50 µg/ml for 30 min and KLFC LiDps at 100 3 
µg/ml for 50 min. The last two steps were repeated to amplify the level of SnCe6 targeted delivery.  4 
Light exposure 5 
 SnCe6 was excited with a 633 nm HeNe laser (Melles Griot, Carlsbad, Ca) defocused with a 6 
microscope ocular lens. For light exposure the plate was inverted as described above. The plate was 7 
placed at a specified distance from the objective so that the area of the beam was slightly larger than 8 
the area of the floor of the well. Irradiance (Wcm-2) was determined using a photometer. The total 9 
fluence (Jcm-2) was determined by the product of the irradiance and the exposure time. The 10 
illumination time was 20 min (1,200 s) to achieve a total fluence of 14 Jcm-2 which is in the standard 11 
range for antimicrobial PDT (25) 12 
Viability assay 13 
 Membrane integrity of A. actinomycetemcomitans cells in biofilm microcolonies was 14 
evaluated using the BacLight Live/Dead bacterial viability assay (Molecular Probes) (28). Saline 15 
solutions of SYTO 9 and propidium iodide at concentrations recommended by the manufacturer of 16 
the kit (L-7012; Molecular Probes) were used. Propidium iodide (red) penetrates cells with 17 
compromised membranes while SYTO 9 (green) penetrates all cells. PMT sensitivity for the red and 18 
green channels was optimized so that signal was well above background while minimizing bleed 19 
through. These optimized settings were used for each experiment. Red/green ratio was quantified as 20 
the ratio of pixel intensities of the red and green channels evaluated using MetaMorph software 21 
(Molecular Devices Corporation, Downingtown, PA). Microcolonies were selected for analysis, 22 
excluding dark regions between the colonies. This was accomplished by "thresholding". Histograms 23 
of number of pixels versus pixel brightness were constructed and then truncated to omit the dark 24 
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 10 
inter-colony regions. Mean pixel brightness of the associated truncated histograms was then 1 
calculated. The relationship between the red/green ratio and membrane disruption was assessed by 2 
using the red/green ratio induced in biofilms exposed 0.1 mg/ml chlorhexidine digluconate (CHG) 3 
for 1h as an internal standard for each experiment. In preliminary studies we determined that 4 
exposure of cell suspensions of A. actinomycetemcomitans used for biofilm inocula to 0.1 mg/ml 5 
chlorhexidine digluconate for 1h reduces CFU by 3 orders of magnitude. (The rough colony A. 6 
actinomycetemcomitans variant remains primarily in cell aggregates even when dispersed into 7 
liquid).  8 
Statistical analysis 9 
 Efficacy of the targeted SnCe6 was evaluated by a paired t test. Three independent replicates 10 
were performed on separate days. Each experiment included 3 or 4 untreated biofilms with the wells 11 
for these biofilms distributed along a row of ten wells. Two targeted biofilms exposed to light as 12 
well as one well with a non-targeted biofilm exposed to light were also included in each experiment. 13 
These wells were located towards one side of the row to minimize the effect of scattered laser light 14 
on unexposed wells. Red/green ratios were normalized to the red/green ratio obtained for internal 15 
standard (the 0.1 mg/ml CHG condition). Means of within experiment replicates were used for the 16 
paired t test. 17 
 18 
Results 19 
Transport of LiDps into A. actinomycetemcomitans biofilm microcolonies 20 
 Transport of KLFC LiDps into A. actinomycetemcomitans microcolonies was characterized 21 
using SLCM. The absence of targeting allowed transport kinetics to be measured without the 22 
additional factor of binding kinetics. The well was filled with a solution of KLFC LiDps, 23 
fluorescently tagged via the peptidyl cysteine residues, and the time course of increase in 24 
fluorescence was measured at locations at the base of microcolonies (near the substratum), and in 25 
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 11 
the interior of microcolonies with respect to the view in the plane of the substratum. The A. 1 
actinomycetemcomitans biofilm was stained with a red nucleic acid stain prior to the transport study 2 
(Fig.1A). Fig.1B shows the mean kinetics of transport of the fluorescently tagged KLFC LiDps to 3 
locations at the base of 16 A. actinomycetemcomitans microcolonies. Fig.1B indicates that the mean 4 
concentration of dodecamer in the interior regions of A. actinomycetemcomitans microcolonies 5 
reached a level of approximately 60 % of the fluorescent signal in the bulk (between microcolonies) 6 
at 20 min. 7 
  Figs. 1C and D are SLCM images taken at a section proximal to the substratum interface 5 8 
and 20 min (respectively) after exposure of the biofilm to the fluorescently tagged KLFC LiDps. 9 
Locations where data were acquired to construct Fig.1B are indicated. There was a 20% increase in 10 
the fluorescence signal from the bulk solution (between the microcolonies) between the first and 11 
second time points (4 and 8 min, respectively) which then remained constant. This is likely due to 12 
diffusion of the multimeric protein into a static boundary layer near the substratum, accompanied, 13 
perhaps, by non-specific adsorption onto the substratum. The 100% value for fluorescence was 14 
taken as the value for the later times points in order to construct the data presented in Fig.1B.  One 15 
possible reason for the exclusion of fluorescence from peripheral regions of the microcolonies may 16 
be that there is a greater density of extracellular matrix in these regions. However, we have no direct 17 
evidence for this. 18 
  19 
Dual functionalized LiDps for targeting 20 
 The 12 terminating cysteines (C) on the tetrapeptides of the KLFC LiDps construct provide 21 
ideal attachment sites for targeting moieties since they are displaced from the exterior dodecamer 22 
shell (23) by the peptide spacer (KLFC). The biotinylation reagent provides a further extension of 23 
the spacer length (3 nm) between the biotin and the dodecamer external surface. The covalent 24 
addition of one biotin maleimide functional group to each of the monomeric subunits was confirmed 25 
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 12 
using LC/MS (Fig.2A and B). Some oxidation of the biotinylated product is indicated by the 1 
appearance of small higher molecular weight bands spaced 16 Da apart (26). 2 
 Biotinylated KLFC LiDps (KLFC LiDps-B) was further functionalized with either Alexa 3 
Fluor 488 (KLFC-LiDps-B-AF) or SnCe6 (KLFC-LiDps-B-SnCe6). KLFC-LiDps-B-AF is an 4 
analog of the KLFC-LiDps-B-SnCe6 with Alexa Fluor 488 substituted for SnCe6. Succinimidyl 5 
esters of these compounds were added to intrinsic lysines of the dodecamer. Association of these 6 
functionalities with the dodecamer was confirmed by co-migration of a distinguishing absorbance 7 
band of the Alexa Fluor 488 or SnCe6 with the dodecamer on SEC (Fig.2C and D). Extensive 8 
dialysis did not reduce the ratio of functional group to protein (determined spectrophotometrically) 9 
indicating that the functional groups were covalently bound to the lysines.  10 
Targeting of A. actinomycetemcomitans biofilm microcolonies with LiDps 11 
 KLFC-LiDps-B-AF was used to characterize targeting of A. actinomycetemcomitans biofilm 12 
since SnCe6 fluorescence was not in an appropriate range for SLCM detection. The targeting 13 
approach used for both KLFC-LiDps-B-AF and KLFC-LiDps-B-SnCe6 is illustrated in Fig.3A. 14 
Streptavidin was used to couple KLFC-LiDps-B-AF to biotinylated Aa-mAb bound to the biofilm 15 
cells. The loading of the fluorophor per Aa-mAb epitope binding site was subsequently increased by 16 
repeating cycles of exposure to streptavidin and biotinylated dodecamer, with a consequent 17 
amplification in fluorescence signal. The first row of SLCM images in Fig.3 (B, i, ii, iii) are 48h A. 18 
actinomycetemcomitans biofilms targeted with KLFC-LiDps-B-AF. The mean fluorescence within 19 
48h A. actinomycetemcomitans biofilm microcolonies was increased by factors of 3.4 and 6.3 for 20 
one and two repeated cycles of exposure to streptavidin and KLFC-LiDps-B-AF, respectively (Fig.3 21 
B, ii, iii). Binding to A. actinomycetemcomitans microcolonies was primarily mediated through the 22 
specific Aa-mAb/epitope interaction as indicated by the much lower fluorescent signal acquired 23 
when the Aa-mAb was omitted from the series of reactions (Fig.3 C, i, ii, iii). There was a slight 24 
amount of non-specific binding of the dodecamer to the A. actinomycetemcomitans biofilm 25 
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 13 
microcolonies indicated by a fluorescent signal in the green channel which was above background, 1 
and which was also amplified by cycles of exposure to streptavidin and KLFC-LiDps-B-AF. The 2 
KLFC-LiDps-B-AF fluorescence within microcolonies was lower by factors of 248, 802 and 8 3 
(Fig.3B and C from left to right, respectively) when Aa-mAb was omitted from the reaction. 4 
 Images of sections in the plane of the interface and sections taken perpendicular to the 5 
interface both indicated that the fluorescence distribution in the microcolonies was non-uniform for 6 
48 h biofilms targeted with dodecamer, with a more dense concentration of fluorescence near the 7 
peripheries of microcolonies. In contrast, the fluorescence originating from non-specific interactions 8 
(Fig. 3 C) was uniformly distributed throughout the A. actinomycetemcomitans colonies. This is 9 
more evident if the images are contrast-enhanced (data not shown). This result suggests that the 10 
distribution of fluorescence in targeted A. actinomycetemcomitans microcolonies reflects the Aa-11 
mAb epitope distribution in 48 h A. actinomycetemcomitans microcolonies, rather than originating 12 
from hindered transport (consistent with the transport study). 13 
 In contrast to 48 h targeted biofilms, 24 h targeted biofilms show a more even uniform 14 
distribution of KLFC-LiDps-B-AF (Fig. 3, last row, D, E, and F). The brightness/contrast of these 15 
images was optimized (identically) to show the pattern of fluorescence. Fig. 3E shows a magnified 16 
view of a microcolony. A comparison of pixel brightness within the two squares showed that 17 
fluorescence even within the darkest region of a large microcolony was twice that of the 18 
background. Fig.3F shows the level of non-specific binding of the KLFC-LiDps-B-AF to the A. 19 
actinomycetemcomitans microcolonies when the Aa-mAb was omitted.   20 
Light induced membrane disruption of SnCe6 targeted A. actinomycetemcomitans biofilm 21 
 The red/green color ratio determined from the viability assay upon exposure of biofilms to 22 
0.1 mg/ml CHG for 1 h was used as an internal standard for assessing the efficacy of light induced 23 
membrane disruption of SnCe6 targeted cells. The rationale for this was that CHG has been shown 24 
previously to be efficacious against A. actinomycetemcomitans biofilms (48) and the primary mode 25 
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of action of CHG is membrane disruption (24). According to the viability assay there was a clear 1 
break point between 0.1 mg/ml CHG and 0.01 mg/ml CHG (Supplementary Material, Fig.1S). A. 2 
actinomycetemcomitans biofilms exposed to these two CHG concentrations for 1h were included in 3 
each experiment as internal standards.  4 
 A. actinomycetemcomitans biofilms were targeted with KLFC-LiDps-B-SnCe6 using the 5 
same protocol as for KLFC-LiDps-B-AF (Fig.3A). In a preliminary experiment we obtained no 6 
evidence of membrane disruption of 48 h biofilms. We proceeded to test 24 h biofilms and obtained 7 
evidence of membrane disruption for biofilms targeted using two cycles of exposure to streptavidin 8 
followed by KLFC-LiDps-B-SnCe6. We attempted to gather data demonstrating a correlation 9 
between loss of viability and cycles of amplification using the KLFC-LiDps-B-SnCe6 construct but 10 
the variability was too great to make any strong claims. As indicated in Fig.4 membrane disruption 11 
induced by exposure of SnCe6 targeted A. actinomycetemcomitans microcolonies to light (Fig.4B) 12 
was intermediate between that of untreated microcolonies (Fig.4A) and microcolonies exposed to 13 
0.1 mg/ml CHG (Fig.4C). The mean red/green ratio for SnCe6 targeted microcolonies exposed to 14 
light compared to those exposed to 0.1 mg/ml CHG was 0.62 (SD 0.21) for three independent 15 
experiments.  The red/green ratio for the SnCe6 targeted microcolonies exposed to light was higher 16 
than both untreated microcolonies and SnCe6 targeted microcolonies not exposed to light at the 5% 17 
level of confidence (Table 1). The red/green ratio for the SnCe6 targeted microcolonies exposed to 18 
light was higher than both microcolonies exposed to light but not targeted with SnCe6 and 19 
microcolonies exposed to 0.01 mg/ml CHG at the 10% level of confidence (Table 1). Data for all 20 
three experiments are in Supplementary Material (Fig.2S). 21 
 22 
Discussion 23 
 Our results indicate that the KLFC-LiDps can be transported into A. actinomycetemcomitans 24 
microcolonies during a reasonable time period, that cells within the microcolonies can be targeted 25 
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 15 
with the dodecamer and that this multimeric protein can be used as a vehicle for targeted delivery of 1 
a photosensitizer to A. actinomycetemcomitans microcolonies. The susceptibility of A. 2 
actinomycetemcomitans biofilms to antimicrobials has been shown to decrease as the biofilm 3 
matures (45). Consistent with these results, we observed no light induced decrease in viability of 48 4 
h biofilms targeted with photosensitizer, while there was clear evidence of light induced membrane 5 
disruption of 24 h biofilms targeted with photosensitizer. The more evenly distributed Aa-mAb 6 
epitope distribution in 24 h A. actinomycetemcomitans microcolonies may have been partially 7 
responsible for this result (Fig. 3). In general, mechanical plaque removal is not sufficient to 8 
completely eliminate oral biofilm (2), and this has been shown to be the case for A. 9 
actinomycetemcomitans (34). Selective killing of A. actinomycetemcomitans early stage biofilms 10 
would presumably enhance the ability of commensals to compete with A. actinomycetemcomitans 11 
during recolonization (47), thus conferring a measure of colonization resistance to periodontal 12 
tissues (33). In addition, the recolonization by a consortium in which commensals were predominant 13 
might aid in establishing a healthy immune balance at diseased sites, allowing periodontal tissues 14 
more leverage to eliminate intracellular (invasive) A. actinomycetemcomitans.   15 
 Transport of macromolecules through a polymicrobial oral biofilm was found previously to 16 
be significantly hindered (49). The shape of the data curves presented in Fig.1B suggests that the 17 
LiDps dodecamer attained about 90% saturation in central regions at the base of the A. 18 
actinomycetemcomitans biofilm microcolonies at 20 min. The fluorescence in these regions at 20 19 
min was about 35 - 95 % of the fluorescence in the bulk , with a mean of about 60%. An extensive 20 
review of the literature indicated that the diffusion coefficient of macromolecules the size of the 21 
LiDps (molecular weight, 222 kDa) could be reduced in biofilms by as much as a factor of about 22 
0.02 compared to the diffusion coefficient in water (39). This translates to about 17 min to reach 23 
90% saturation in a planar slab 30 µm thick, indicating that the transport kinetics of the LiDps 24 
dodecamer that we measured are consistent with previous studies. In terms of eventual clinical 25 
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application, the mean fluorescence at 5 min in locations that were relatively inaccessible was 1 
approximately 25% of the bulk fluorescence. Estimating the volume excluded by the cells to be 2 
50%, the intercellular concentration at 5 min in the interior portions of the biofilm was about 50% of 3 
the bulk concentration. This may be sufficient to effectively target A. actinomycetemcomitans 4 
biofilms during a 5 min exposure period if the affinity coefficient for binding of the targeting 5 
moieties is sufficiently high. 6 
 Advantages of the targeting approach we used in this study include modularity and ability to 7 
amplify the loading. The modularity of the system allows different targeting moieties to be 8 
combined easily with a single functionalized multimeric protein. We have shown previously that 9 
loading of a small molecule onto a 12 nm 24 subunit small heat shock protein from Methanococcus 10 
jannaschii can be increased substantially by incorporating a polymer confined to the interior cavity 11 
delineated by the protein shell (1). Although the nucleation and stepwise growth required to 12 
synthesize the polymer is fairly sophisticated, the process can be streamlined to produce large 13 
quantities of the biotinylated product. Recently, we synthesized an asymmetrically biotinylated 14 
LiDps dodecamer that enables one step targeting via an antibody while preserving the modular 15 
design (42). Another advantage of our targeting approach is the possibility of increasing the loading 16 
with a sequence of applications. Previously, we characterized signal amplification that can be 17 
obtained by exploiting the streptavidin/biotin interaction to obtain clusters of the CCMV capsule 18 
bound at nucleation sites (40). We acquired AFM images to confirm formation of CCMV clusters at 19 
a planar interface (43). Here, we used a similar approach to increase the photosensitizer loading at 20 
targeted sites. Although the amplification in the fluorescence signal shown in Fig. 3B suggests that 21 
aggregated clusters of the dodecamer are forming at sites of Aa-mAb binding as depicted in Fig.3A 22 
we have no direct evidence to support this interpretation. With respect to clinical relevance, topical 23 
application of a sequence of agents may be feasible if the application time is within 5 min. However, 24 
for some applications it will obviously be desirable to have a one step administration. 25 
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 The antimicrobial action of photosensitizers against gram negative bacteria is known to be 1 
less than against gram positive bacteria (19, 25). One method to enhance photosensitizer action 2 
against gram negative bacteria is to couple the photosensitizer to a cationic peptide or polymer (20, 3 
46). This enhancement may originate from the localized concentration of photosensitizer near the 4 
cell membrane, or, alternatively, from disruption of the membrane by the cationic moieties. Since 5 
the dodecamer is too large to have entered cells by any known process, the former explanation is 6 
consistent with the loss of viability we observed for cells targeted with photosensitizer and exposed 7 
to light. We cannot claim that cells in biofilms were in fact killed since we have no direct evidence 8 
for this. However, our results indicate that membranes of photosensitizer targeted cells exposed to 9 
light were more permeable than controls, and thus these cells may be sufficiently damaged to 10 
substantially decrease their competitiveness when growing in a developing oral consortium.  11 
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Figure legends 1 
FIG.1. Transport of fluorescently tagged KLFC-LiDps into A. actinomycetemcomitans biofilm 2 
microcolonies. A) Biofilm microcolonies stained with SYTO 59  (4.167 µm tick spacing). 3 
Microcolonies circled with the dashed lines are the same ones circled in C (below). B) Transport 4 
kinetics of fluorescently tagged KLFC-Dps into regions at the base of biofilm microcolonies; The 5 
solid line connects data which are the mean of measurements at 16 locations; error bars are the 6 
standard deviations. C) Section acquired near the substratum 4 min after exposure of the biofilm to 7 
the fluorescently tagged KLFC-LiDps; regions used to acquire the data presented in B are indicated. 8 
D) Section acquired near the substratum 21 min after exposure of the biofilm to the fluorescently 9 
tagged KLFC-LiDps. 10 
 11 
FIG.2. Dual functionalized KLFC-LiDps. A, B) LC/MS deconvolutions of mass spectra of 12 
monomeric subunits of the dodecamer. A) mass of non-functionalized KLFC-LiDps monomeric 13 
subunits (18540 Da); B) mass of biotinylated KLFC-LiDps (KLFC-LiDps-B) monomeric subunits 14 
(19065 Da). The difference in mass between A and B (525 Da) is expected for addition of the 15 
biotinylation reagent to the cysteines. The deconvolved spectrum in B indicates that all the 12 16 
subunits of KLFC-LiDps were biotinylated. C, D) Size exclusion chromatograms of biotinylated 17 
KLFC-LiDps tagged with Alexa-fluor 488 (KLFC-LiDps-B-AF)  (C) or functionalized with the 18 
SnCe6 (KLFC-LiDps-B-photosensitizer) (D). The solid lines are the absorbance at 280 nm (protein). 19 
The dashed lines indicate the absorbances of the Alexa-fluor 488 (488 nm) or photosensitizer (410 20 
nm) (C and D, respectively). The vertical straight line indicates the position at which the dodecamer 21 
elutes.  22 
 23 
FIG.3. Targeting of  A. actinomycetemcomitans biofilm microcolonies with KLFC-LiDps-B-AF. A. 24 
Illustration of presumed cluster formation produced by cycles of exposure to streptavidin followed 25 
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by KLFC-LiDps-B-AF resulting in an amplification of the fluorescent signal at sites of Aa-mAb 1 
binding; Ab: Aa-mAb; StAv: streptavidin; Dps: KLFC-Dps; CWE: cell wall epitope; 1 cycle means 2 
Aa-mAb followed by streptavidin followed by KLFC-Dps; B. 48 h biofilm microcolonies targeted 3 
with biotinylated KLFC-Dps tagged with Alexa-fluor 488 for 1 to 3 cycles of exposure to 4 
streptavidin followed by KLFC-LiDps-B-AF; 1 cycle (i); 2 cycles (ii); 3 cycles (iii); C. Biofilms 5 
treated the same as in B except that the Aa-mAb was omitted from the first step. D. 24 h biofilm 6 
targeted with biotinylated KLFC-Dps tagged with Alexa-fluor 488; E. magnified view of a selected 7 
portion of D, showing the relatively even distribution of fluorescence from the targeted dodecamer; 8 
pixel brightness computed for two small regions indicated that even the darkest region of the 9 
microcolonies was twice as fluorescent as the background (small squares). F. Biofilm was treated 10 
the same as D but the Aa-mAb was omitted.  11 
 12 
FIG.4. Membrane disruption of A. actinomycetemcomitans biofilm microcolonies targeted with the 13 
photosensitizer assessed by the BacLight Live/Dead bacterial viability assay (images of biofilm 14 
microcolonies); A) not treated; B) targeted with photosensitizer and exposed to light; C) exposed to 15 
0.1 mg/ml CHG. 16 
 17 
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 27 
Table 1. Statistical level of significance for targeted light induced membrane damage 1 
 2 
Pair1 Relative damage2 p value3 
PSL,NT 3.78 0.0184 
PSL,PS 2.77 0.0286 
PSL,L 4.94 0.0995 
PSL,CHG(.01) 4.29 0.0904 
 3 
1PSL: targeted with photosensitizer and exposed to light;  4 
NT: not treated;  5 
PS: targeted with photosensitizer, no light exposure;  6 
L: exposed to light, not-targeted;  7 
CHG(.01): exposed to 0.01 mg/ml CHG 8 
 9 
2Ratio of mean red/green ratios (PSL/paired condition) for three independent experiments 10 
 11 
3Determined by a paired t test for three independent experiments 12 
 13 
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